|
|
Article: Phase III Clinical Trial Initiated.(by Abgenix Inc.)
- Article from:
- Immunotherapy Weekly
- Article date:
- January 16, 2000
CopyrightCOPYRIGHT 2000 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2000 JAN 16 - (NewsRx.com) -- Abgenix, Inc., is initiating a Phase III clinical trial comparing its antibody, ABX-CBL, with standard therapy for patients with steroid-resistant graft-versus-host disease (srGVHD), a serious, life-threatening disorder.
Abgenix also indicated that it would seek a corporate partner to assist with the development and commercialization of ABX-CBL.
Abgenix is pursuing the Phase III trial of ABX-CBL based on promising results of a 59-patient Phase II trial of the drug. In that trial, srGVHD patients receiving higher doses of ABX-CBL had more than twice the 180-day survival rate observed in the lowest dose cohort, according to ...